PharmaCyte Biotech announced that its board of directors has authorized a second share repurchase program to repurchase up to $10M of PharmaCyte’s outstanding common stock. This second share repurchase authorization is effective immediately for a two-year period. PharmaCyte expects to fund the program with its available cash. The company enacted a similar program in June 2022.
Published first on TheFly
